Table 4.

Odds ratio (OR) and 95% confidence interval (CI) of clinical status and GAS5 rs145204276 genotypic frequencies in 334 prostate cancer patients with age over 65 years.

Variable	Genotypic frequencies
rs145204276	ins/ins (N=157)	ins/del + del/del (N=177)	OR (95% CI)	p value
PSA at diagnosis (ng/mL)
≤ 10	57 (36.3%)	81 (45.8%)	1.00	p=0.080
> 10	100 (63.7%)	96 (54.2%)	0.676 (0.435-1.049)
Pathologic Gleason grade group
1+2+3	122 (77.7%)	146 (82.5%)	1.00	p=0.274
4+5	35 (22.3%)	31 (17.5%)	0.740 (0.431-1.270)
Clinical T stage
1+2	123 (78.3%)	155 (87.6%)	1.00	p=0.024*
3+4	34 (21.7%)	22 (12.4%)	0.513 (0.286-0.923)
Pathologic T stage
2	78 (49.7%)	91 (51.4%)	1.00	p=0.752
3+4	79 (50.3%)	86 (48.6%)	0.933 (0.607-1.434)
Pathologic N stage
N0	134 (85.4%)	164 (92.7%)	1.00	p=0.032*
N1	23 (14.6%)	13 (7.3%)	0.462 (0.225-0.946)
Seminal vesicle invasion
No	112 (71.3%)	142 (80.2%)	1.00	p=0.057
Yes	45 (28.7%)	35 (19.8%)	0.613 (0.370-1.018)
Perineural invasion
No	33 (21.0%)	50 (28.2%)	1.00	p=0.127
Yes	124 (79.0%)	127 (71.8%)	0.676 (0.408-1.119)
Lymphovascular invasion
No	122 (77.7%)	154 (87.0%)	1.00	p=0.025*
Yes	35 (22.3%)	23 (13.0%)	0.521 (0.292-0.927)
D'Amico classification
Low risk/ Intermediate risk	62 (39.5%)	77 (43.5%)	1.00	p=0.458
High risk	95 (60.5%)	100 (56.5%)	0.848 (0.548-1.312)

The ORs with analyzed by their 95% CIs were estimated by logistic regression models. * p value < 0.05 as statistically significant.